Bard PowerPort Lawsuit Update October 2026: $40M Verdict, 4,140 Cases & Who Still Qualifies
As of October 2026, more than 4,100 Bard PowerPort lawsuits are pending in federal multidistrict litigation (MDL 3081) in Arizona — and the litigation just turned: on September 4, 2026, a federal jury awarded $40 million to a plaintiff whose port catheter fractured and lodged in her heart. More bellwether trials run through February 2027, and attorneys are still accepting new claims.
Key facts
- MDL 3081 (In re: Bard Implanted Port Catheter Products Liability Litigation) was centralized in the U.S. District Court for the District of Arizona in August 2023; about 4,140 cases were pending as of October 1, 2026.
- The second bellwether trial ended September 4, 2026, with a $40 million plaintiff verdict in Divelbliss v. Becton Dickinson — the first plaintiff win in the MDL.
- The third bellwether trial, an infection and sepsis case, ran October 13–30, 2026; further trials are set for December 2026 and February 2027.
- The suits allege Bard's port catheters can fracture, migrate, or cause infections and blood clots, sometimes requiring additional surgery.
- Most mass-tort attorneys handle these cases on a contingency fee — you pay nothing unless you win.
For more video explainers on medical and financial topics, see Problem Solved on YouTube.
What Is the Bard PowerPort Lawsuit About?
A Bard PowerPort is a small implanted device, usually placed under the skin of the chest, that gives doctors long-term vein access for chemotherapy, IV medications, and blood draws. The lawsuits allege the catheter portion — made from materials including ChronoFlex polyurethane and silicone — can degrade inside the body, then fracture into pieces, migrate through the bloodstream, or trigger severe infections and blood clots.
C.R. Bard made the devices; the company is now owned by Becton, Dickinson and Company (BD). Plaintiffs argue the ports were defectively designed and the warnings about fracture and migration risks were inadequate. This is not a class action. MDL stands for multidistrict litigation: cases from across the country are grouped before one judge for coordinated discovery, but each plaintiff must still prove their own injuries to receive compensation.
The $40 Million Divelbliss Verdict
The turning point came on September 4, 2026, when an Arizona federal jury awarded $40 million to Kimberly Divelbliss. Her Bard PowerPort catheter had fractured, and a fragment traveled to her heart, causing serious cardiac complications that required surgical removal. The jury found the device defectively designed and the warnings inadequate.
The first bellwether trial, involving plaintiff Robert Cook, had ended in May 2026 with a defense verdict. One defense win followed by a $40 million plaintiff win tells attorneys the litigation can go either way on the facts — which is why the upcoming trials matter.
Trial Schedule: What Comes Next
The court has set a steady drumbeat of trials. After Cook (April–May 2026, defense verdict) and Divelbliss (August–September 2026, $40 million plaintiff verdict), the third bellwether — an infection and sepsis case — went to a jury October 13–30, 2026. Two more bellwether trials are calendared for December 2026 and February 2027, covering additional fracture and thrombosis claims.
Each case turns on its own medical records, device model, and documented injuries. But plaintiff verdicts historically push defendants toward a global settlement program. Do not wait for the trials to finish before acting — filing deadlines do not pause for trial schedules.
Which Devices and Injuries Are Covered?
Claims are being investigated across several Bard implanted-port products: the Bard PowerPort, Powerflow, SlimPort, X-Port, MRI Ports, Groshong catheter, Titanium Port, and Vaccess CT systems. If you had any Bard implanted port and suffered a fracture, migration, infection, or clot, your device may be part of this litigation — attorneys can usually identify the model from your implant card or operative report.
Reported injuries include catheter fracture, migration, deep vein thrombosis, bloodstream infections and sepsis, vessel perforation, hemorrhaging, cardiac arrhythmia, and — in the most severe cases — wrongful death. Similar device litigations, like the Essure and transvaginal mesh cases, show that organized medical records separate strong claims from weak ones.
Who Qualifies and What Does It Cost?
You may qualify if you had a Bard implanted port and later experienced a fracture, migration, serious infection, blood clot, or another complication requiring medical treatment or additional surgery. Family members may have claims where a loved one died after a port complication. An attorney reviews the device model, the complication timeline, and the medical records to determine whether your facts fit.
Compensation varies widely by case. No reliable public per-case figures exist because most settlements are confidential, and your compensation depends on your specific facts — injury severity, medical costs, lost income, and your state's laws. Be skeptical of any ad promising a specific payout. What is standard is the fee arrangement: most mass-tort lawyers work on a contingency fee, typically around one-third of any recovery, so you pay nothing out of pocket and nothing at all unless you win. Firms experienced in device MDLs, such as those handling the Depo-Provera litigation, offer free case evaluations and collect records with your authorization.
Filing Deadline: Do Not Wait
Every state sets its own deadline, and device cases often turn on when the injury was discovered, not when the device was implanted. Some states allow only about one year from discovery, while most allow two to three years. Because the deadline analysis is fact-specific and unforgiving, waiting for the bellwether trials to conclude is a mistake: once your deadline passes, no verdict can revive your claim. Two steps help now: locate your implant card or operative report to identify the exact device model, and write down your complication timeline while memories are fresh.
Who Benefits From This — and Who Does Not
About 4,140 Bard PowerPort cases were pending in MDL 3081 as of October 1, 2026, and the September 4, 2026 Divelbliss verdict — $40 million, the first plaintiff win in the MDL — changed the picture. Most mass-tort attorneys take these cases on a contingency fee, so you pay nothing unless you win. But the verdict helps some people far more than others.
Who benefits:
- Patients with a Bard implanted port who suffered a fracture, migration, infection, or blood clot — An attorney can usually identify your device model from your implant card or operative report, then review the complication timeline and your medical records to see whether your facts fit.
- Family members of a patient who died after a port complication — The article notes family members may have claims where a loved one died after a port complication.
- Patients who were discouraged by the first bellwether loss — Robert Cook’s May 2026 defense verdict was followed by the $40 million Divelbliss win; do not wait for the December 2026 and February 2027 trials to finish, because filing deadlines do not pause for trial schedules.
Who does not benefit:
- Patients with a Bard port but no complication — In an MDL each plaintiff must prove their own injuries; a device alone, without a fracture, migration, infection, clot, or other documented complication, is not a claim.
- Anyone expecting the $40 million verdict as a payout — Compensation varies by injury severity, medical costs, lost income, and state law, and no reliable public per-case figures exist because most settlements are confidential.
- Anyone who waits for a global settlement before acting — No settlement is reported in the article, and filing deadlines do not pause while trials run through February 2027.
Related reading: Transvaginal Mesh Lawsuit: Who Qualifies, What the Claims Say, and How to File.
Frequently Asked Questions
Is the Bard PowerPort lawsuit a class action?
No. It is a federal multidistrict litigation (MDL 3081). In a class action, one representative case decides the outcome for everyone; in an MDL, cases are coordinated for discovery but each plaintiff must prove their own injuries to receive compensation.
How many Bard PowerPort lawsuits have been filed?
About 4,140 cases were pending in MDL 3081 as of the Judicial Panel on Multidistrict Litigation's October 1, 2026 report, with hundreds of new cases added in recent months.
What was the $40 million verdict?
On September 4, 2026, a federal jury awarded $40 million to Kimberly Divelbliss, whose Bard PowerPort catheter fractured and lodged in her heart. It was the second bellwether trial and the first plaintiff win in the MDL.
Has there been a settlement?
No global settlement has been announced. The litigation is in the bellwether-trial phase, with trials scheduled through February 2027. Settlement talks in MDLs often follow the pattern of bellwether results, so the upcoming trials are closely watched.
How much does it cost to file a claim?
Nothing out of pocket. Mass-tort attorneys handle these cases on a contingency fee — typically around one-third of any recovery — so you pay nothing unless you win, and case evaluations are free.
Who does not benefit from the Bard PowerPort lawsuit?
People with a Bard port but no fracture, migration, infection, clot, or other documented complication do not benefit, because each plaintiff must prove their own injuries. Anyone expecting the $40 million Divelbliss verdict as a fixed payout will also be disappointed: compensation depends on individual facts, and no reliable public per-case figures exist.
This article is general information about the Bard PowerPort litigation, not legal advice. Laws and deadlines vary by state; consult a qualified attorney about your specific situation.